Atsena Therapeutics

OverviewSuggest Edit

Atsena Therapeutics is a clinical-stage ocular gene therapy company developing treatments for inherited forms of blindness. It develops an adeno-associated virus technology platform tailored to overcome hurdles presented by inherited retinal disease. Atsena's medical programs include gene therapies for leading forms of Leber congenital amaurosis and Usher syndrome.

TypePrivate
Founded2019
HQDurham, NC, US
Websiteatsenatx.com

Latest Updates

Employees (est.) (Sept 2021)19
Cybersecurity ratingDMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Atsena Therapeutics Office Locations

Atsena Therapeutics has offices in Durham and Boston
Show all (2)

Atsena Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2019

Atsena Therapeutics total Funding

$63.2 m

Atsena Therapeutics latest funding size

$55 m

Time since last funding

10 months ago

Atsena Therapeutics investors

Atsena Therapeutics's latest funding round in December 2020 was reported to be $55 m. In total, Atsena Therapeutics has raised $63.2 m
Show all financial metrics

Atsena Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

D

65/100

SecurityScorecard logo

Atsena Therapeutics Online and Social Media Presence

Embed Graph

Atsena Therapeutics News and Updates

Atsena Therapeutics Appoints Linda B. Couto, PhD, as Chief Scientific Officer

Dr. Couto strengthens leadership team with extensive AAV and ocular gene therapy expertise Dr. Couto strengthens leadership team with extensive AAV and ocular gene therapy expertise

Atsena Therapeutics Appoints Jennifer Wellman to Board of Directors

DURHAM, N.C., July 12, 2021 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced the appointment of Jennifer Wellman to its board of directors. Ms. Wellman, a …

Atsena Therapeutics Receives Orphan Drug Designation from the FDA for Novel Gene Therapy to Treat Genetic Eye Disease LCA1

Phase I/II clinical trial is ongoing in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D Phase I/II clinical trial is ongoing in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D

Atsena Therapeutics Appoints Kenji Fujita, MD, as Chief Medical Officer

Dr. Fujita brings extensive clinical development and regulatory strategy experience Dr. Fujita brings extensive clinical development and regulatory strategy experience

Atsena Therapeutics Raises $55M in Series A Financing

Atsena Therapeutics, a Durham, N.C. and Boston, MA-based clinical-stage gene therapy company, closed a $55m Series A financing

Atsena Therapeutics Frequently Asked Questions

  • When was Atsena Therapeutics founded?

    Atsena Therapeutics was founded in 2019.

  • How many employees does Atsena Therapeutics have?

    Atsena Therapeutics has 19 employees.

  • Who are Atsena Therapeutics competitors?

    Competitors of Atsena Therapeutics include Midwest Medical, AnchorDx and Lupagen.

  • Where are Atsena Therapeutics offices?

    Atsena Therapeutics has offices in Durham and Boston.

  • How many offices does Atsena Therapeutics have?

    Atsena Therapeutics has 2 offices.